OncoMatch/Clinical Trials/NCT02962661
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
Is NCT02962661 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Mesenchymal Stem Cell Transplantation and Mesenchymal Stem Cell Transplantation for cardiomyopathy.
Treatment: Mesenchymal Stem Cell Transplantation · Mesenchymal Stem Cell Transplantation — This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Tumor Agnostic
Performance status
NYHA 1–3
Prior therapy
Must have received: anthracycline
treatment with anthracyclines for any malignancy at any dose at any time
Cannot have received: trastuzumab
Exception: allowed if persistent LV dysfunction present 90 days after discontinuation
For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab.
Cannot have received: trastuzumab
Trastuzumab treatment within the last 3 months
Lab requirements
Liver function
Liver function tests <= 3 x upper limit of normal
Cardiac function
LVEF <= 40% documented; NYHA class I, II, III; not NYHA class IV; no inotropic dependence; no cardiogenic shock; no significant valvular disease (AS with AVA <1.5 and severe AR and MR); no left ventricular thrombus; no mechanical or bioprosthetic heart valve; no unstable or life-threatening arrhythmia
LVEF <= 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy. Documented NYHA class I, II and III. Significant Valvular Disease. (AS with AVA <1.5 and severe AR and MR) [excluded]. Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram [excluded]. Mechanical or Bioprosthetic heart valve [excluded]. Cardiogenic shock [excluded]. Unstable or life-threatening arrhythmia [excluded]. Inotropic dependence [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify